TITLE

Double blind placebo controlled multicentre study of ginkgolide B in treatment of acute exacerbations of multiple sclerosis. The Ginkgolide Study Group in multiple sclerosis

AUTHOR(S)
Brochet, B; Guinot, P; Orgogozo, J M; Confavreux, C; Rumbach, L; Lavergne, V
PUB. DATE
March 1995
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Mar1995, Vol. 58 Issue 3, p360
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
No abstract available.
ACCESSION #
66076551

 

Related Articles

  • Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. St�ve, Olaf; Kita, Mariko; Pelletier, Daniel; Fox, Robert J; Stone, Jerome; Goodkin, Donald E; Zamvil, Scott S // Multiple Sclerosis (13524585);Jun2004 Supplement, Vol. 10 Issue 1S, pS58 

    Mitoxantrone (Novantrone�) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an...

  • Treatment of fatigue with pemoline.  // Inside MS;Fall/Winter92, Vol. 10 Issue 3, p11 

    Reports the effectiveness of pemoline in treating short-term fatigue associated with multiple sclerosis. Double blind placebo controlled study of pemoline.

  • Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. St�ve, Olaf; Kita, Mariko; Pelletier, Daniel; Fox, Robert J; Stone, Jerome; Goodkin, Donald E; Zamvil, Scott S // Multiple Sclerosis (13524585);May2004 Supplement, Vol. 10 Issue 3S, pS58 

    Mitoxantrone (Novantrone�) was the first drug approved in western Europe and North A merica for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an...

  • Mitoxantrone as a potential therapy for primary progressive multiple sclerosis. St�ve, Olaf; Kita, Mariko; Pelletier, Daniel; Fox, Robert J.; Stone, Jerome; Goodkin, Donald E.; Zamvil, Scott S. // Multiple Sclerosis (13524585);Jun2004 Supplement, Vol. 10, p58 

    Mitoxantrone (Novantrone�) was the first drug approved in western Europe and North America for treatment of secondary progressive multiple sclerosis (SPMS) and progressive relapsing MS (PRMS). Pharmacological properties of mitoxantrone, its role in SPMS, the study rational and design of an...

  • Safety of oral cladribine clarified in RRMS patients.  // Reactions Weekly;10/10/2009, Issue 1273, p5 

    The article reports on the results of phase III CLARITY study on the safety and tolerability of oral cladribine for relapsing-remitting multiple sclerosis (RRMS). The results of the 96-week, Phase III, double-blind placebo-controlled study favored the drug. This report was presented at the 25th...

  • Fampridine Prolonged Release Improves Walking Ability and Balance in Patients with Multiple Sclerosis. Vinall, Phil // MD Conference Express;Jun2014, Vol. 14 Issue 6, p12 

    Treatment with prolonged-release fampridine results in sustained, clinically meaningful improvement in walking ability and balance in patients with multiple sclerosis (MS). This article presents the results of Exploratory Study to Assess the Effect of Fampridine on Walking Ability and Balance in...

  • Second MAB trial needs participants.  // Inside MS;Spring98, Vol. 16 Issue 1, p6 

    Announces the need for participants for a double-blind, placebo-controlled clinical trials on the use of a monoclonal antibody called Antegren (natalizumab) for the treatment of acute multiple sclerosis (MS), around the United States. Description of the Antegren; Participation criteria; Contact...

  • Effectiveness of amantadine in reducing relapses in multiple sclerosis. Plaut, G. S. // Journal of the Royal Society of Medicine;Feb1987, Vol. 80 Issue 2, p91 

    Fifty-three patients with multiple sclerosis were assessed in a double-blind multicentre study for the effect of amantadine. The patients were observed in general practices for up to four years. Relapses occurred in 5 of the 24 patients treated with amantadine and in 14 of the 29 placebo-treated...

  • Vitamin D and Multiple Sclerosis.  // Townsend Letter;Jan2013, Issue 354, p47 

    The article reviews the article "A randomised, double blind, placebo controlled trial with vitamin D3 as an add on treatment to interferon beta-1b in patients with multiple sclerosis," by M. Soilu-Hanninen et al. published in the 2012 issue of "Journal of Neurology, Neurosurgery & Psychiatry."

  • Efficacy and Safety of the Platelet-Activating Factor Receptor Antagonist BN 52021 (Ginkgolide B) in Patients with Severe Sepsis. van Ackern, K.; Bender, H. -J.; Hof, H.; Kox, W.; Victor, N.; Funk, P.; Kieser, M.; Köhler, S.; Krausch, D.; Marzi, I.; Menges, T.; Schmidt, H.; Albrecht, D. M. // Clinical Drug Investigation;2004, Vol. 24 Issue 3, p137 

    Objective: To evaluate the efficacy and safety of the natural platelet-activating factor receptor antagonist, BN 52021 (ginkgolide B) in the treatment of patients with severe sepsis related to Gram-negative and mixed bacterial infection. Design and setting: Prospective, randomised, double-blind,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics